Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 10;26:141–157. doi: 10.1016/j.omto.2022.06.005

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s)

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Efficacy of LV-IFNα in murine MB49 intravesical model

(A) Kaplan-Meier plot showing percent survival in C57Bl/6, MB49 intravesical disease model treated with vehicle (Syn3), LV-Ctrl, and LV-IFNα (p = 0.0004). (B) H&E staining of whole-mount bladder tissues with corresponding Ki67 staining in MB49 is shown. (C) IHC for CD4 and CD8 T cells on MB49 intravesical tumors treated with Syn3 (vehicle), LV-Ctrl, and LV-IFNα vectors is shown. (D) Quantification of CD4 and CD8 cells in the MB49 intravesical model is shown. (E) Heatmap of 190 significantly altered genes at an FDR cutoff 0.05 and log2 fold change of one between LV-IFNα and LV-Ctrl groups. (F) GSEA analysis shows enrichment of apoptosis, natural-killer-cell-mediated cytotoxicity, and Fc-gamma-receptor-mediated cytotoxicity (top panel) and EGFR tyrosine kinase inhibitor resistance, platinum drug resistance in LV-IFNα-treated tumors, and enrichment of bladder cancer gene set in LV-Ctrl group.